Bristol-Myers Squibb Company (BMY)
| Market Cap | 154.04B |
| Revenue (ttm) | 46.74B |
| Net Income (ttm) | 6.68B |
| Shares Out | 2.13B |
| EPS (ttm) | 3.07 |
| PE Ratio | 23.60 |
| Forward PE | 9.97 |
| Dividend | $2.19 (3.02%) |
| Ex-Dividend Date | Jan 5, 2023 |
| Volume | 5,185,346 |
| Open | 72.99 |
| Previous Close | 72.99 |
| Day's Range | 72.34 - 73.45 |
| 52-Week Range | 62.90 - 81.44 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 83.20 (+14.84%) |
| Earnings Date | Feb 2, 2023 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients w... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is $83.2, which is an increase of 14.84% from the latest price.
News
Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
PRINCETON N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval ...
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the...
Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to Decline
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced topline results from TRANSCEND CLL 004, a Phase 1/2, open-label, single-arm, multicenter study evaluating Breyanzi ...
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million
PRINCETON, N.J.--(BUSINESS WIRE)--The Robert A. Winn Diversity in Clinical Trials Award Program (Winn Award Program) established by the Bristol Myers Squibb Foundation (BMSF) today announced that Am...
7 Dividend-Paying Large-Cap Stocks to Buy in January
With the markets likely to stay volatile during 2023, playing defensively remains a solid strategy to ride out this tough investing environment. One way you can implement such a strategy is by increas...
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
Not every stock went down in 2022. Shares in some the biggest pharmaceutical companies rose in price.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Healthcare Stocks Had a Strong 2022. It Isn't Too Late to Buy.
Profits in the sector tend to be stable even if hard times hurt earnings elsewhere, so the current high inflation and rising rates, represent a chance for the shares to shine.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan's 41st Annual Healthcare Conference on Monday, January 9, 2023. Giovanni Cafo...
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York
NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) has completed the previously announced sale of its manufacturing facility in Syracuse, New York to LOTTE BIOLOGICS.
What's Driving Growth For Bristol Myers Squibb Stock?
Bristol Myers Squibb stock (NYSE: BMY) has seen an 18% rise this year, far better than the broader S&P500 index, which is down 20%.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
THE COLLABORATION ADDS TWO DRUG DISCOVERY PROJECTS TO THE PORTFOLIO AND DESIGNATES A TARGET-BASED PROGRAMME FOR DEVELOPMENT EVOTEC RECEIVES PAYMENTS IN TOTAL OF US$ 26 M FROM BRISTOL MYERS SQUIBB HAMB...
Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023
NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) will announce results for the fourth quarter of 2022 on Thursday, February 2, 2023. Company executives will review financial results and ad...
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of results and presentation of new research from its multiple myeloma portfolio across targets...
Health care will continue to be a leader going into next year, says Strategas' Chris Verrone
Chris Verrone, Strategas head of technical analysis, joins 'Closing Bell: Overtime' to discuss why he thinks there will be opportunity in health care stocks in 2023.
Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & Deere
Today's Research Daily features update on the Q4 earnings season and new research reports on Merck (MRK), Bristol-Myers (BMY) and Deere (DE).
Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.